Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Capital Expenditures (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Capital Expenditures data on record, last reported at $5000.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures fell 80.0% year-over-year to $5000.0; the TTM value through Sep 2025 reached $106000.0, up 26.19%, while the annual FY2024 figure was $105000.0, 4.55% down from the prior year.
  • Capital Expenditures reached $5000.0 in Q3 2025 per DNTH's latest filing, down from $46000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $129000.0 in Q2 2022 and bottomed at -$46000.0 in Q3 2022.
  • Average Capital Expenditures over 4 years is $28600.0, with a median of $25000.0 recorded in 2024.
  • The widest YoY moves for Capital Expenditures: up 241.3% in 2023, down 83.72% in 2023.
  • A 4-year view of Capital Expenditures shows it stood at $29000.0 in 2022, then plummeted by 65.52% to $10000.0 in 2023, then skyrocketed by 210.0% to $31000.0 in 2024, then crashed by 83.87% to $5000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $5000.0 in Q3 2025, $46000.0 in Q2 2025, and $24000.0 in Q1 2025.